Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

As FDA shortages lift, patients and physicians explore new options for continued treatment with compounded GLP-1 medications.

Amidst the dangers of fake or illegitimate compounded semaglutide, NovoCare Pharmacy offers reliable access to authentic, FDA-approved Wegovy in our once-weekly, single-dose pen.” The federal ...

The manufacturer of a brand-name drug can sell it for up to 20 years. When the brand-name drug’s patent expires, multiple manufacturers can create generic versions. This marketplace competition ...

Work is continuing so that the drug, and similar medicines, can be issued under medical card schemes to slash costs.

the pen availability, right for packaging the product, it is not as available. Production costs are higher, so we don't expect to see prices going down as much in this category. Semaglutide and ...

the loss of patent protection for a big insulin brand would have been a deal for Novo Nordisk, surging sales of the GLP-1 agonist class of diabetes therapies like Ozempic (semaglutide) have ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

“Even as we face patent expiration for Semaglutide, we’ll probably still launch the product in markets and [drive] volume growth, and to do that we need to have a very large manufacturing ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...